{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T15:21:00Z","timestamp":1795101660152,"version":"4.10.3"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T00:00:00Z","timestamp":1695427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T00:00:00Z","timestamp":1695427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773170, 81970713, and 82170817"],"award-info":[{"award-number":["81773170, 81970713, and 82170817"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Liver cancer stem cells (LCSCs) are recognized as key contributors to hepatocarcinogenesis, progression, and recurrence. Consequently, eradicating LCSCs has a great chance of increasing long-term survival in patients with liver cancer. Parthenolide (PTL), a natural sesquiterpene lactone product, possesses robust antitumor activity. However, the effects of PTL on LCSCs and underlying mechanisms remain unknown. Here we show that administration of PTL stimulated cell cycle arrest at the G1 phase, induced apoptosis, and decreased the stemness of LCSCs. Further research indicates that PTL caused the production of ROS and the reduction of oxidative phosphorylation (OXPHOS) and mitochondrial membrane potential (MMP) levels of LCSCs. RNA sequencing (RNA-Seq) further shows that PTL decreased SLC25A1 expression at the mRNA level and that inhibition of SLC25A1 synergistically decreased the expression of IDH2 and several pivotal genes involved in mitochondrial respiratory chain complex, resulting in the production of ROS and mitochondrial dysfunction. In addition, the inhibitory effect of PTL on mitochondrial function and self-renewal capacity of LCSCs was abolished by the knockdown of SLC25A1 or treatment with SLC25A1 inhibitor CTPI-2. Importantly, PTL prevented liver cancer growth in vivo without clearly causing toxicity. Our research shows that PTL inhibits the growth and stemness of LCSCs through SLC25A1-mediated mitochondrial function. PTL may be a potential candidate natural agent for liver cancer treatment.<\/jats:p>","DOI":"10.1038\/s41420-023-01640-6","type":"journal-article","created":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T05:01:56Z","timestamp":1695445316000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["A novel SLC25A1 inhibitor, parthenolide, suppresses the growth and stemness of liver cancer stem cells with metabolic vulnerability"],"prefix":"10.1038","volume":"9","author":[{"given":"Zhichun","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyue","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lichao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,23]]},"reference":[{"key":"1640_CR1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"1640_CR2","doi-asserted-by":"crossref","first-page":"188314","DOI":"10.1016\/j.bbcan.2019.188314","volume":"1873","author":"D Anwanwan","year":"2020","unstructured":"Anwanwan D, Singh SK, Singh S, Saikam V, Singh R. Challenges in liver cancer and possible treatment approaches. Biochim Biophys Acta Rev Cancer. 2020;1873:188314.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"1640_CR3","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41392-020-00264-x","volume":"5","author":"A Huang","year":"2020","unstructured":"Huang A, Yang XR, Chung WY, Dennison AR, Zhou J. Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther. 2020;5:146.","journal-title":"Signal Transduct Target Ther"},{"key":"1640_CR4","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/nrclinonc.2015.103","volume":"12","author":"JM Llovet","year":"2015","unstructured":"Llovet JM, Villanueva A, Lachenmayer A, Finn RS. Advances in targeted therapies for hepatocellular carcinoma in the genomic era. Nat Rev Clin Oncol. 2015;12:408\u201324.","journal-title":"Nat Rev Clin Oncol"},{"key":"1640_CR5","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrc3184","volume":"12","author":"LV Nguyen","year":"2012","unstructured":"Nguyen LV, Vanner R, Dirks P, Eaves CJ. Cancer stem cells: an evolving concept. Nat Rev Cancer. 2012;12:133\u201343.","journal-title":"Nat Rev Cancer"},{"key":"1640_CR6","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1056\/NEJMra1804280","volume":"380","author":"MF Clarke","year":"2019","unstructured":"Clarke MF. Clinical and therapeutic implications of cancer stem cells. N Engl J Med. 2019;380:2237\u201345.","journal-title":"N Engl J Med"},{"key":"1640_CR7","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1038\/ncb3039","volume":"16","author":"VS LeBleu","year":"2014","unstructured":"LeBleu VS, O\u2019Connell JT, Gonzalez Herrera KN, Wikman H, Pantel K, Haigis MC, et al. PGC-1alpha mediates mitochondrial biogenesis and oxidative phosphorylation in cancer cells to promote metastasis. Nat Cell Biol. 2014;16:992\u20131003.","journal-title":"Nat Cell Biol"},{"key":"1640_CR8","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1053\/j.gastro.2015.06.007","volume":"149","author":"IS Song","year":"2015","unstructured":"Song IS, Jeong YJ, Jeong SH, Heo HJ, Kim HK, Bae KB, et al. FOXM1-induced PRX3 regulates the stemness and survival of colon cancer cells via maintenance of mitochondrial function. Gastroenterology. 2015;149:1006\u201316.e1009.","journal-title":"Gastroenterology."},{"key":"1640_CR9","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.cmet.2017.09.009","volume":"26","author":"KM Lee","year":"2017","unstructured":"Lee KM, Giltnane JM, Balko JM, Schwarz LJ, Guerrero-Zotano AL, Hutchinson KE, et al. MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation. Cell Metab. 2017;26:633\u201347.e637.","journal-title":"Cell Metab"},{"key":"1640_CR10","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1002\/hep.30622","volume":"70","author":"Z Wei","year":"2019","unstructured":"Wei Z, Jia J, Heng G, Xu H, Shan J, Wang G, et al. Sirtuin-1\/mitochondrial ribosomal protein S5 axis enhances the metabolic flexibility of liver cancer stem cells. Hepatology. 2019;70:1197\u2013213.","journal-title":"Hepatology."},{"key":"1640_CR11","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/ijc.25944","volume":"129","author":"XQ Ye","year":"2011","unstructured":"Ye XQ, Li Q, Wang GH, Sun FF, Huang GJ, Bian XW, et al. Mitochondrial and energy metabolism-related properties as novel indicators of lung cancer stem cells. Int J Cancer. 2011;129:820\u201331.","journal-title":"Int J Cancer"},{"key":"1640_CR12","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1101\/gad.188292.112","volume":"26","author":"M Janiszewska","year":"2012","unstructured":"Janiszewska M, Suva ML, Riggi N, Houtkooper RH, Auwerx J, Clement-Schatlo V, et al. Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells. Genes Dev. 2012;26:1926\u201344.","journal-title":"Genes Dev"},{"key":"1640_CR13","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jhep.2020.12.031","volume":"74","author":"C Raggi","year":"2021","unstructured":"Raggi C, Taddei ML, Sacco E, Navari N, Correnti M, Piombanti B, et al. Mitochondrial oxidative metabolism contributes to a cancer stem cell phenotype in cholangiocarcinoma. J Hepatol. 2021;74:1373\u201385.","journal-title":"J Hepatol"},{"key":"1640_CR14","doi-asserted-by":"crossref","first-page":"17010","DOI":"10.1038\/celldisc.2017.10","volume":"3","author":"P Shi","year":"2017","unstructured":"Shi P, Liu W, Tala, Wang H, Li F, Zhang H, et al. Metformin suppresses triple-negative breast cancer stem cells by targeting KLF5 for degradation. Cell Discov. 2017;3:17010.","journal-title":"Cell Discov"},{"key":"1640_CR15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.freeradbiomed.2013.10.003","volume":"67","author":"M Stapelberg","year":"2014","unstructured":"Stapelberg M, Zobalova R, Nguyen MN, Walker T, Stantic M, Goodwin J, et al. Indoleamine-2,3-dioxygenase elevated in tumor-initiating cells is suppressed by mitocans. Free Radic Biol Med. 2014;67:41\u201350.","journal-title":"Free Radic Biol Med"},{"key":"1640_CR16","volume":"15","author":"B Yan","year":"2015","unstructured":"Yan B, Stantic M, Zobalova R, Bezawork-Geleta A, Stapelberg M, Stursa J, et al. Mitochondrially targeted vitamin E succinate efficiently kills breast tumour-initiating cells in a complex II-dependent manner. BMC Cancer. 2015;15:401.","journal-title":"BMC Cancer"},{"key":"1640_CR17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.3390\/biom11020141","volume":"11","author":"R Mosaoa","year":"2021","unstructured":"Mosaoa R, Kasprzyk-Pawelec A, Fernandez HR, Avantaggiati ML. The mitochondrial citrate carrier SLC25A1\/CIC and the fundamental role of citrate in cancer, inflammation, and beyond. Biomolecules. 2021;11:141.","journal-title":"Biomolecules."},{"key":"1640_CR18","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.mam.2012.05.005","volume":"34","author":"F Palmieri","year":"2013","unstructured":"Palmieri F. The mitochondrial transporter family SLC25: identification, properties and physiopathology. Mol Asp Med. 2013;34:465\u201384.","journal-title":"Mol Asp Med"},{"key":"1640_CR19","volume":"12","author":"Y Yang","year":"2021","unstructured":"Yang Y, He J, Zhang B, Zhang Z, Jia G, Liu S, et al. SLC25A1 promotes tumor growth and survival by reprogramming energy metabolism in colorectal cancer. Cell Death Dis. 2021;12:1108.","journal-title":"Cell Death Dis"},{"key":"1640_CR20","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/s41418-018-0101-z","volume":"25","author":"HR Fernandez","year":"2018","unstructured":"Fernandez HR, Gadre SM, Tan M, Graham GT, Mosaoa R, Ongkeko MS, et al. The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer. Cell Death Differ. 2018;25:1239\u201358.","journal-title":"Cell Death Differ"},{"key":"1640_CR21","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1039\/C9NP00049F","volume":"37","author":"RRA Freund","year":"2020","unstructured":"Freund RRA, Gobrecht P, Fischer D, Arndt HD. Advances in chemistry and bioactivity of parthenolide. Nat Prod Rep. 2020;37:541\u201365.","journal-title":"Nat Prod Rep"},{"key":"1640_CR22","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.biopha.2018.08.139","volume":"107","author":"WH Talib","year":"2018","unstructured":"Talib WH, Al Kury LT. Parthenolide inhibits tumor-promoting effects of nicotine in lung cancer by inducing P53 - dependent apoptosis and inhibiting VEGF expression. Biomed Pharmacother. 2018;107:1488\u201395.","journal-title":"Biomed Pharmacother"},{"key":"1640_CR23","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2016.94","volume":"7","author":"D Carlisi","year":"2016","unstructured":"Carlisi D, Buttitta G, Di Fiore R, Scerri C, Drago-Ferrante R, Vento R, et al. Parthenolide and DMAPT exert cytotoxic effects on breast cancer stem-like cells by inducing oxidative stress, mitochondrial dysfunction, and necrosis. Cell Death Dis. 2016;7:e2194.","journal-title":"Cell Death Dis"},{"key":"1640_CR24","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/CMR.0b013e328333bbe4","volume":"20","author":"K Lesiak","year":"2010","unstructured":"Lesiak K, Koprowska K, Zalesna I, Nejc D, Duchler M, Czyz M. Parthenolide, a sesquiterpene lactone from the medical herb feverfew, shows anticancer activity against human melanoma cells in vitro. Melanoma Res. 2010;20:21\u201334.","journal-title":"Melanoma Res"},{"key":"1640_CR25","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/jcp.22494","volume":"226","author":"D Carlisi","year":"2011","unstructured":"Carlisi D, D\u2019Anneo A, Angileri L, Lauricella M, Emanuele S, Santulli A, et al. Parthenolide sensitizes hepatocellular carcinoma cells to TRAIL by inducing the expression of death receptors through inhibition of STAT3 activation. J Cell Physiol. 2011;226:1632\u201341.","journal-title":"J Cell Physiol"},{"key":"1640_CR26","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1124\/jpet.110.169367","volume":"335","author":"YR Kim","year":"2010","unstructured":"Kim YR, Eom JI, Kim SJ, Jeung HK, Cheong JW, Kim JS, et al. Myeloperoxidase expression as a potential determinant of parthenolide-induced apoptosis in leukemia bulk and leukemia stem cells. J Pharmacol Exp Ther. 2010;335:389\u2013400.","journal-title":"J Pharmacol Exp Ther"},{"key":"1640_CR27","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1182\/blood-2012-08-448852","volume":"121","author":"P Diamanti","year":"2013","unstructured":"Diamanti P, Cox CV, Moppett JP, Blair A. Parthenolide eliminates leukemia-initiating cell populations and improves survival in xenografts of childhood acute lymphoblastic leukemia. Blood. 2013;121:1384\u201393.","journal-title":"Blood."},{"key":"1640_CR28","doi-asserted-by":"crossref","first-page":"555","DOI":"10.7150\/thno.49250","volume":"11","author":"Y Hou","year":"2021","unstructured":"Hou Y, Sun B, Liu W, Yu B, Shi Q, Luo F, et al. Targeting of glioma stem-like cells with a parthenolide derivative ACT001 through inhibition of AEBP1\/PI3K\/AKT signaling. Theranostics. 2021;11:555\u201366.","journal-title":"Theranostics."},{"key":"1640_CR29","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0140-6736(88)92289-1","volume":"2","author":"JJ Murphy","year":"1988","unstructured":"Murphy JJ, Heptinstall S, Mitchell JR. Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet. 1988;2:189\u201392.","journal-title":"Lancet"},{"key":"1640_CR30","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1023\/B:DRUG.0000026256.38560.be","volume":"22","author":"EA Curry 3rd","year":"2004","unstructured":"Curry EA 3rd, Murry DJ, Yoder C, Fife K, Armstrong V, Nakshatri H, et al. Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer. Investig New Drugs. 2004;22:299\u2013305.","journal-title":"Investig New Drugs"},{"key":"1640_CR31","volume":"4","author":"H Liu","year":"2013","unstructured":"Liu H, Zhang W, Jia Y, Yu Q, Grau GE, Peng L, et al. Single-cell clones of liver cancer stem cells have the potential of differentiating into different types of tumor cells. Cell Death Dis. 2013;4:e857.","journal-title":"Cell Death Dis"},{"key":"1640_CR32","volume":"16","author":"K Nio","year":"2017","unstructured":"Nio K, Yamashita T, Kaneko S. The evolving concept of liver cancer stem cells. Mol Cancer. 2017;16:4.","journal-title":"Mol Cancer"},{"key":"1640_CR33","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1159\/000343863","volume":"3","author":"N Oishi","year":"2014","unstructured":"Oishi N, Yamashita T, Kaneko S. Molecular biology of liver cancer stem cells. Liver Cancer. 2014;3:71\u201384.","journal-title":"Liver Cancer"},{"key":"1640_CR34","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.cmet.2015.06.006","volume":"22","author":"PH Willems","year":"2015","unstructured":"Willems PH, Rossignol R, Dieteren CE, Murphy MP, Koopman WJ. Redox homeostasis and mitochondrial dynamics. Cell Metab. 2015;22:207\u201318.","journal-title":"Cell Metab"},{"key":"1640_CR35","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.redox.2015.09.005","volume":"6","author":"J Dan Dunn","year":"2015","unstructured":"Dan Dunn J, Alvarez LA, Zhang X, Soldati T. Reactive oxygen species and mitochondria: A nexus of cellular homeostasis. Redox Biol. 2015;6:472\u201385.","journal-title":"Redox Biol"},{"key":"1640_CR36","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1152\/physrev.00041.2020","volume":"102","author":"JF Garbincius","year":"2022","unstructured":"Garbincius JF, Elrod JW. Mitochondrial calcium exchange in physiology and disease. Physiol Rev. 2022;102:893\u2013992.","journal-title":"Physiol Rev"},{"key":"1640_CR37","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.molcel.2015.12.002","volume":"61","author":"I Martinez-Reyes","year":"2016","unstructured":"Martinez-Reyes I, Diebold LP, Kong H, Schieber M, Huang H, Hensley CT, et al. TCA Cycle and mitochondrial membrane potential are necessary for diverse biological functions. Mol Cell. 2016;61:199\u2013209.","journal-title":"Mol Cell"},{"key":"1640_CR38","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3389\/fonc.2018.00170","volume":"8","author":"J Hlouschek","year":"2018","unstructured":"Hlouschek J, Hansel C, Jendrossek V, Matschke J. The mitochondrial citrate carrier (SLC25A1) sustains redox homeostasis and mitochondrial metabolism supporting radioresistance of cancer cells with tolerance to cycling severe hypoxia. Front Oncol. 2018;8:170.","journal-title":"Front Oncol"},{"key":"1640_CR39","doi-asserted-by":"crossref","first-page":"eabl8716","DOI":"10.1126\/sciadv.abl8716","volume":"8","author":"A Murari","year":"2022","unstructured":"Murari A, Goparaju NSV, Rhooms SK, Hossain KFB, Liang FG, Garcia CJ, et al. IDH2-mediated regulation of the biogenesis of the oxidative phosphorylation system. Sci Adv. 2022;8:eabl8716.","journal-title":"Sci Adv"},{"key":"1640_CR40","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6.","journal-title":"Nat Rev Dis Primers"},{"key":"1640_CR41","doi-asserted-by":"crossref","first-page":"6992","DOI":"10.3390\/ijms21196992","volume":"21","author":"S Mani","year":"2020","unstructured":"Mani S, Swargiary G, Singh KK. Natural agents targeting mitochondria in cancer. Int J Mol Sci. 2020;21:6992.","journal-title":"Int J Mol Sci"},{"key":"1640_CR42","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41575-021-00508-3","volume":"19","author":"TK Lee","year":"2022","unstructured":"Lee TK, Guan XY, Ma S. Cancer stem cells in hepatocellular carcinoma\u2014from origin to clinical implications. Nat Rev Gastroenterol Hepatol. 2022;19:26\u201344.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1640_CR43","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41571-019-0293-2","volume":"17","author":"JA Clara","year":"2020","unstructured":"Clara JA, Monge C, Yang Y, Takebe N. Targeting signalling pathways and the immune microenvironment of cancer stem cells\u2014a clinical update. Nat Rev Clin Oncol. 2020;17:204\u201332.","journal-title":"Nat Rev Clin Oncol"},{"key":"1640_CR44","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/nature13611","volume":"514","author":"A Viale","year":"2014","unstructured":"Viale A, Pettazzoni P, Lyssiotis CA, Ying H, Sanchez N, Marchesini M, et al. Oncogene ablation-resistant pancreatic cancer cells depend on mitochondrial function. Nature. 2014;514:628\u201332.","journal-title":"Nature."},{"key":"1640_CR45","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-022-03447-y","volume":"20","author":"S Sriramkumar","year":"2022","unstructured":"Sriramkumar S, Sood R, Huntington TD, Ghobashi AH, Vuong TT, Metcalfe TX, et al. Platinum-induced mitochondrial OXPHOS contributes to cancer stem cell enrichment in ovarian cancer. J Transl Med. 2022;20:246.","journal-title":"J Transl Med"},{"key":"1640_CR46","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.semcancer.2017.06.012","volume":"47","author":"R Loureiro","year":"2017","unstructured":"Loureiro R, Mesquita KA, Magalhaes-Novais S, Oliveira PJ, Vega-Naredo I. Mitochondrial biology in cancer stem cells. Semin Cancer Biol. 2017;47:18\u201328.","journal-title":"Semin Cancer Biol"},{"key":"1640_CR47","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.phrs.2018.11.020","volume":"139","author":"J Skoda","year":"2019","unstructured":"Skoda J, Borankova K, Jansson PJ, Huang ML, Veselska R, Richardson DR. Pharmacological targeting of mitochondria in cancer stem cells: An ancient organelle at the crossroads of novel anti-cancer therapies. Pharmacol Res. 2019;139:298\u2013313.","journal-title":"Pharmacol Res"},{"key":"1640_CR48","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.tibs.2019.11.001","volume":"45","author":"JJ Ruprecht","year":"2020","unstructured":"Ruprecht JJ, Kunji ERS. The SLC25 Mitochondrial Carrier Family: Structure and Mechanism. Trends Biochem Sci. 2020;45:244\u201358.","journal-title":"Trends Biochem Sci"},{"key":"1640_CR49","doi-asserted-by":"crossref","first-page":"105132","DOI":"10.1016\/j.phrs.2020.105132","volume":"161","author":"R Peng","year":"2020","unstructured":"Peng R, Zhang M, Wang H, Lin J, Wang H, Wang F, et al. Advances in understanding the vital role of the mitochondrial citrate carrier (CIC) in metabolic diseases. Pharmacol Res. 2020;161:105132.","journal-title":"Pharmacol Res"},{"key":"1640_CR50","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","volume":"389","author":"J Bruix","year":"2017","unstructured":"Bruix J, Qin S, Merle P, Granito A, Huang Y-H, Bodoky G, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:56\u201366.","journal-title":"Lancet"},{"key":"1640_CR51","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","volume":"391","author":"M Kudo","year":"2018","unstructured":"Kudo M, Finn RS, Qin S, Han K-H, Ikeda K, Piscaglia F, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163\u201373.","journal-title":"Lancet"},{"key":"1640_CR52","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1136\/gutjnl-2015-309501","volume":"66","author":"V Tovar","year":"2017","unstructured":"Tovar V, Cornella H, Moeini A, Vidal S, Hoshida Y, Sia D, et al. Tumour initiating cells and IGF\/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma. Gut. 2017;66:530\u201340.","journal-title":"Gut."},{"key":"1640_CR53","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1002\/hep.28117","volume":"62","author":"DX Guan","year":"2015","unstructured":"Guan DX, Shi J, Zhang Y, Zhao JS, Long LY, Chen TW, et al. Sorafenib enriches epithelial cell adhesion molecule-positive tumor-initiating cells and exacerbates a subtype of hepatocellular carcinoma through TSC2-AKT cascade. Hepatology. 2015;62:1791\u2013803.","journal-title":"Hepatology."},{"key":"1640_CR54","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s13287-022-02888-y","volume":"13","author":"T Takao","year":"2022","unstructured":"Takao T, Masuda H, Kajitani T, Miki F, Miyazaki K, Yoshimasa Y, et al. Sorafenib targets and inhibits the oncogenic properties of endometrial cancer stem cells via the RAF\/ERK pathway. Stem Cell Res Ther. 2022;13:225.","journal-title":"Stem Cell Res Ther"},{"key":"1640_CR55","doi-asserted-by":"crossref","first-page":"8247","DOI":"10.3892\/mmr.2015.4422","volume":"12","author":"JB Kim","year":"2015","unstructured":"Kim JB, Lee M, Park SY, Lee S, Kim HR, Lee HS, et al. Sorafenib inhibits cancer side population cells by targeting cJun N-terminal kinase signaling. Mol Med Rep. 2015;12:8247\u201352.","journal-title":"Mol Med Rep"},{"key":"1640_CR56","first-page":"1865","volume":"27","author":"Y Jia","year":"2012","unstructured":"Jia Y, Liu H, Zhuang Q, Xu S, Yang Z, Li J, et al. Tumorigenicity of cancer stem-like cells derived from hepatocarcinoma is regulated by microRNA-145. Oncol Rep. 2012;27:1865\u201372.","journal-title":"Oncol Rep"},{"key":"1640_CR57","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s00280-011-1708-7","volume":"69","author":"Y Jia","year":"2012","unstructured":"Jia Y, Zhang W, Liu H, Peng L, Yang Z, Lou J. Inhibition of glutathione synthesis reverses Kruppel-like factor 4-mediated cisplatin resistance. Cancer Chemother Pharmacol. 2012;69:377\u201385.","journal-title":"Cancer Chemother Pharmacol"},{"key":"1640_CR58","doi-asserted-by":"crossref","first-page":"105964","DOI":"10.1016\/j.phrs.2021.105964","volume":"174","author":"H Zhang","year":"2021","unstructured":"Zhang H, Lu J, Liu H, Guan L, Xu S, Wang Z, et al. Ajugol enhances TFEB-mediated lysosome biogenesis and lipophagy to alleviate non-alcoholic fatty liver disease. Pharmacol Res. 2021;174:105964.","journal-title":"Pharmacol Res"}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-023-01640-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-023-01640-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-023-01640-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,19]],"date-time":"2023-11-19T05:17:54Z","timestamp":1700371074000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-023-01640-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,23]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1640"],"URL":"https:\/\/doi.org\/10.1038\/s41420-023-01640-6","relation":{},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,23]]},"assertion":[{"value":"20 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests. Part of the graphical abstract was created with BioRender.com.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study\u2019s protocol was approved by the ethics committee of China-Japan Friendship Hospital. Our experiments followed the guidelines outlined in the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"350"}}